Oligodendrocyte

Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing

Retrieved on: 
Tuesday, June 22, 2021
Medical devices, Surgery, FDA, Genetics, Clinical trials, Stem cells, Other Health, Biotechnology, Pharmaceutical, Health, Branches of biology, Neurotrauma, Spinal cord, Medical emergencies, Biology of bipolar disorder, Oligodendrocyte, Spinal cord injury, Rehabilitation Trauma Center, Lineage Cell Therapeutics

It is a privilege to report that our novel OPC1 program will be returning to clinical testing earlier than anticipated.

Key Points: 
  • It is a privilege to report that our novel OPC1 program will be returning to clinical testing earlier than anticipated.
  • Pursuant to that agreement, Lineage may integrate the Neurgain PSD system into a late-stage clinical trial and, if approved, commercial use of OPC1 for the treatment of patients with spinal cord injury.
  • The cost of a lifetime of care for a severe spinal cord injury can be as high as $5 million.
  • OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements in motor recovery in individuals with subacute spinal cord injuries.

Penn Dental Medicine Study Shows How HIV Infection Impacts Brain's White Matter

Retrieved on: 
Friday, June 18, 2021
Hepatotoxins, Medical specialties, Prevention of HIV/AIDS, Retroviridae, Health, HIV/AIDS, Pandemics, HIV, Oligodendrocyte, Zidovudine, HIV-associated neurocognitive disorder

PHILADELPHIA, June 18, 2021 /PRNewswire/ -- It's long been known that people living with HIV experience a loss of white matter in their brains.

Key Points: 
  • PHILADELPHIA, June 18, 2021 /PRNewswire/ -- It's long been known that people living with HIV experience a loss of white matter in their brains.
  • Earlier work by a team from Penn Dental Medicine and Children's Hospital of Philadelphia (CHOP) found that antiretroviral therapy (ART)the lifesaving drugs that many with HIV use dailycan reduce white matter, but it wasn't clear how the virus itself contributed to this loss.
  • In a new study using both human and rodent cells, the team has determined how HIV prevents the myelin-making brain cells called oligodendrocytes from maturing, reducing white matter production.
  • "Even when people with HIV have their disease well-controlled by antiretrovirals, they still have the virus present in their bodies, so this study came out of our interest in understanding how HIV infection itself affects white matter," says Kelly Jordan-Sciutto , professor at Penn Dental Medicine and the study's co-senior author.

New Research Study Investigates Metformin as a Therapy to Promote Brain Repair and Reduce Disability in Children and Young Adults with MS

Retrieved on: 
Tuesday, February 2, 2021
Branches of biology, Drugs, Glial cells, Myelin, Oligodendrocyte, Metformin, Health sciences, Preclinical development

These partnerships are critical for leveraging more research dollars and increased impact for the benefit of Canadian health.

Key Points: 
  • These partnerships are critical for leveraging more research dollars and increased impact for the benefit of Canadian health.
  • Preclinical evidence shows metformin enhances oligodendrocytes cells that produce myelin and promotes white matter repair in animal models and in youth with radiation-induced brain injury.
  • This research aims to translate these preclinical findings from animal and human studies into clinical practice by conducting a pilot feasibility trial.
  • This strategic funding valued at $118M has benefitted approximately 196 world-class research groups and 3,300 trainees and has catalyzed24clinical trials.

Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for the Treatment of Spinal Cord Injury

Retrieved on: 
Tuesday, December 8, 2020
Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Branches of biology, Biology, Stem cells, Glial cells, Life sciences, Biotechnology, Biology of bipolar disorder, Oligodendrocyte, Lineage Cell Therapeutics, Stem-cell therapy, Spinal Cord Injuries, OPC1, the OPC1 Clinical Study, Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on OPC1 , its oligodendrocyte progenitor cell (OPC) allogeneic transplant for the treatment of acute spinal cord injuries (SCI).

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on OPC1 , its oligodendrocyte progenitor cell (OPC) allogeneic transplant for the treatment of acute spinal cord injuries (SCI).
  • The cost of a lifetime of care for a severe spinal cord injury can be as high as $5 million.
  • OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements in motor recovery in individuals with acute spinal cord injuries (SCI).
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for Spinal Cord Injury

Retrieved on: 
Thursday, June 25, 2020
Oncology, Health, Stem cells, Genetics, Clinical trials, Biotechnology, Branches of biology, Stem cells, Biology, Cell biology, Glial cells, Lineage Cell Therapeutics, Oligodendrocyte, Stem-cell therapy, OPC1, the OPC1 Clinical Study, Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today provided an update on OPC1 , the Companys oligodendrocyte progenitor cell (OPC) therapy for the treatment of acute spinal cord injury (SCI).

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today provided an update on OPC1 , the Companys oligodendrocyte progenitor cell (OPC) therapy for the treatment of acute spinal cord injury (SCI).
  • Lineage intends to meet with the U.S. Food and Drug Administration (FDA) to discuss further development of the OPC1 program by the end of 2020.
  • OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements to motor recovery in individuals with acute spinal cord injuries (SCI).
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program

Retrieved on: 
Friday, November 15, 2019
FDA, Health, Stem cells, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Glial cells, Stem cells, Biology, Cell biology, Biology of bipolar disorder, Oligodendrocyte, Stem-cell therapy, Geron Corporation, the SCiStar Clinical Study, OPC1, Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided an update on OPC1 , the Companys oligodendrocyte progenitor cell (OPC) therapy currently being tested in a Phase I/IIa clinical trial, the SCiStar Study , for the treatment of acute spinal cord injury (SCI).

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided an update on OPC1 , the Companys oligodendrocyte progenitor cell (OPC) therapy currently being tested in a Phase I/IIa clinical trial, the SCiStar Study , for the treatment of acute spinal cord injury (SCI).
  • We remain extremely excited about the potential for OPC1 to provide enhanced motor recovery to patients with spinal cord injuries.
  • OPC1 is an oligodendrocyte progenitor cell (OPC) therapy currently being tested in a Phase I/IIa clinical trial known as SCiStar for the treatment of acute spinal cord injuries.
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

Lineage Cell Therapeutics Announces Issuance of U.S. Patent for Method of Treating Spinal Cord Injury With Stem Cell-Derived Oligodendrocyte Progenitor Cells

Retrieved on: 
Wednesday, September 4, 2019
Health, Stem cells, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Biology, Life sciences, Stem cells, Induced stem cells, Biotechnology, Developmental biology, Glial cells, Oligodendrocyte progenitor cell, Cellular differentiation, Oligodendrocyte, Spinal cord injury research, OPC1, Lineage Cell Therapeutics, Inc.

10,286,009, entitled Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury covering methods for utilizing pluripotent stem cell-derived oligodendrocyte progenitor cells (OPCs) for the treatment of spinal cord injury (SCI).

Key Points: 
  • 10,286,009, entitled Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury covering methods for utilizing pluripotent stem cell-derived oligodendrocyte progenitor cells (OPCs) for the treatment of spinal cord injury (SCI).
  • OPC1 cells are produced by directing the developmental lineage of pluripotent cell lines to generate a proprietary and consistent population of oligodendritic cells.
  • OPC1 is currently being tested in Phase I/IIa clinical trial known as SCiStar, for the treatment of acute spinal cord injuries.
  • With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials.

Frost & Sullivan Publishes Immediate Update Report on Kadimastem Ltd.: World's First successful transplant of embryonic stem cells in ALS patients

Retrieved on: 
Thursday, October 11, 2018
Biology, Stem cells, Cell biology, Biotechnology, Glial cells, Induced stem cells, Embryology, Embryonic stem cell, Beta cell, Insulin, Astrocyte, Oligodendrocyte

Kadimastem published an immediate report on October 9, 2018.

Key Points: 
  • Kadimastem published an immediate report on October 9, 2018.
  • The company reported on the world's first transplantation of embryonic stem cells and thecompletion of 5 patients' enrollment for Cohort A.
  • However, the recruitment of 5 patients and successful transplantation increases the probability of success of the entire clinical trial.
  • oligodendrocytes and astrocytes) and insulin secreting beta cells, derived from human embryonic stem cells.

Frost & Sullivan Publishes Immediate Update Report on Kadimastem Ltd.: World's First successful transplant of embryonic stem cells in ALS patients

Retrieved on: 
Thursday, October 11, 2018
Biology, Stem cells, Cell biology, Biotechnology, Glial cells, Induced stem cells, Embryology, Embryonic stem cell, Beta cell, Insulin, Astrocyte, Oligodendrocyte

Kadimastem published an immediate report on October 9, 2018.

Key Points: 
  • Kadimastem published an immediate report on October 9, 2018.
  • The company reported on the world's first transplantation of embryonic stem cells and thecompletion of 5 patients' enrollment for Cohort A.
  • However, the recruitment of 5 patients and successful transplantation increases the probability of success of the entire clinical trial.
  • oligodendrocytes and astrocytes) and insulin secreting beta cells, derived from human embryonic stem cells.